(Q24197989)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

1 reference

title

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

10 March 2020

main subject

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Alieksei Seniukovich

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

10 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

CD010115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Withdrawal of treatment in the ISOLDE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Impact of preventing exacerbations on deterioration of health status in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Cardiovascular events in patients with COPD: TORCH study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Methods for therapeutic trials in COPD: lessons from the TORCH trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Beclomethasone/formoterol in the management of COPD: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Rapid fall in lung density following smoking cessation in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Does addition of inhaled steroid to combined bronchodilator therapy affect health status in patients with COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroids in COPD: quantifying risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Self-management education for patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Indirect comparisons of competing interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Development of fluticasone propionate and comparison with other inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Pulmonary rehabilitation for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroids and the increased risk of pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroids in COPD and the risk of serious pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Smoking cessation for chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Conceptual and Technical Challenges in Network Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

[Risk of pneumonia with inhaled corticosteroids for stable chronic obstructive pulmonary disease patients]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

Effects of long-term treatment with corticosteroids in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

ADRB2 polymorphisms and budesonide/formoterol responses in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

Withdrawal from and study design of the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010115.PUB2

7 January 2021

10.1002/14651858.CD010115.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

551303

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615270%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

551303

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

551303